Novartis strategic growth highlights were summarized for investors at 2024 J.P. Morgan Healthcare Conference.
Outlining our focused strategy in our core therapeutic areas and technology platforms, alongside our attractive growth prospects and robust pipeline as an innovative medicines company, our CEO, Vas Narasimhan explained why Novartis is an attractive shareholder value creation opportunity.
*This video uses audio from the webcasted event.*
J.P. Morgan Healthcare Conference
Event Date: January 08, 2024
Full webcast here: go.novartis.social/49012mq
Full presentation here: go.novartis.social/49bnIQX
Novartis JPM HC 2024 Coverage: go.novartis.social/48Pur36
Investor Relations: go.novartis.social/42fgWHH
Investor Events: go.novartis.social/42m0qpq
Novartis Strategy: go.novartis.social/3Sj4ZMn
Disclaimer: J.P. Morgan Healthcare Conference live event contains forward-looking statements. Such forward-looking statements are subject to significant known and unknown risks and uncertainties. Visit our website for more information: go.novartis.social/49bnIQX
The J.P. Morgan Healthcare conference live event also contains non-IFRS measures. An explanation of non-IFRS measures can be found on our website go.novartis.social/3ShGoHY.
Learn more: go.novartis.social/48Pur36